Shares of SMS Pharmaceuticals jumped more than 7% in early morning trade on Thursday, following a major regulatory update from the company. The Hyderabad-based pharma firm announced the successful closure of a recent US Food and Drug Administration (USFDA) inspection at its Central Laboratory Analytical Services facility in Gagillapur.
The inspection, carried out from June 23 to June 25, 2025, concluded with zero Form 483 observations. SMS Pharma has now received the Establishment Inspection Report (EIR) with a “No Action Indicated” (NAI) status, signaling a clean audit and compliance with USFDA standards.
This positive regulatory outcome is expected to boost investor confidence and strengthen the company’s credibility in the global pharmaceutical market.
SMS Pharma shares were up 7.60% at ₹249.00 apiece around 9.34 am. It has declined 2.99% this year, so far.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
